Wire · regulatory
Lawmakers urge FDA to enact new China policies after 3 gene therapy deaths
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 August 2026 · Fusion42 review
Following three patient deaths in gene therapy clinical trials in China, U.S. lawmakers urged the FDA to tighten policies on accepting Chinese clinical data, including requiring recent FDA audits of trial sites and reviewing products approved based on such data.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must reassess relying on Chinese gene therapy clinical data for U.S. approvals as tighter FDA scrutiny opens risks for your product strategy and market access. This is a critical compliance and approval hurdle shifting before your next trial or filing.
◆ Coverage
1 source · 21 Aug 2026
◆ Related on Wire
◆ Topics